The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Detection of biomarkers for esophageal cancer pathologic complete response (pathCR) in OE33 and NCI-H460 control cell lines using a clinical standard operating procedure (SOP) protocol.
Robert W. Cook
Employment or Leadership Position - Castle Biosciences
Stock Ownership - Castle Biosciences
Research Funding - Castle Biosciences
Jaffer A. Ajani
No relevant relationships to disclose
Landon Inge
Research Funding - Castle Biosciences